Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ONS 44th Annual Congress /
Benefits and challenges of using PARP inhibitors to treat metastatic breast cancer

11th - 14th Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.05.19
Views: 1970

Kimberly Halla - Arizona Oncology Associates PC, Scottsdale, USA

Kimberly Halla speaks to ecancer at ONS 2019 about the benefits and challenges for oncology nurses of using PARP inhibitors to treat metastatic breast cancer.

She outlines how PARP inhibitors, first used to treat ovarian cancer, have now been found to also be effective in treating metastatic breast cancer.

Kimberly also describes how beneficial PARP inhibitors are to the patient in terms of being able to take these oral therapies at home.

This programme has been supported by an unrestricted educational grant from Pfizer. 

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation